Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neuromyelitis Optica 1Myasthenia Gravis 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Busulfan 3thymoglobulin 2Cyclosporine 2Cyclophosphamide 2Antilymphocyte Serum 2Alemtuzumab 2treosulfan 1sargramostim 1ravulizumab 1merphos 1bryostatin 1 1X-Rays 1Transplantation, Homologous 1Sirolimus 1Observation 1Granulocyte-Macrophage Colony-Stimulating Factor 1Etoposide 1Cyclosporins 1Bryostatins 1Bone Marrow Transplantation 1Basiliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemoglobinuria, Paroxysmal × ravulizumab × Classical hematology × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔